galactosamine has been researched along with ethyl pyruvate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, ZJ; Han, XQ; Li, X; Wang, LK; Wang, LW | 1 |
| Hu, K; Huang, J; Jiang, R; Li, L; Lin, L; Lv, X; Shen, Y; Tang, L; Wan, J; Yang, Y; Zhang, L; Zhou, H | 1 |
2 other study(ies) available for galactosamine and ethyl pyruvate
| Article | Year |
|---|---|
Ethyl pyruvate prevents inflammatory factors release and decreases intestinal permeability in rats with D-galactosamine-induced acute liver failure.
Topics: Animals; Anti-Inflammatory Agents; Bacterial Translocation; Biomarkers; Chemical and Drug Induced Liver Injury; Cytoprotection; Disease Models, Animal; Endotoxins; Galactosamine; Inflammation Mediators; Intestinal Mucosa; Liver; Liver Failure, Acute; Male; Permeability; Pyruvates; Rats; Rats, Wistar; Time Factors | 2013 |
Activation of PKM2 metabolically controls fulminant liver injury via restoration of pyruvate and reactivation of CDK1.
Topics: Animals; Apoptosis; CDC2 Protein Kinase; Galactosamine; Hepatocytes; Lipopolysaccharides; Liver; Liver Diseases; Male; Mice; Mice, Inbred BALB C; Pyridazines; Pyrroles; Pyruvate Kinase; Pyruvates; Pyruvic Acid | 2021 |